【礼来(LLY.US)IL-23p19单抗mirikizumab获批克罗恩病新适应症】1月15日,礼来(LLY.US)宣布,其IL-23p19单抗mirikizumab(Omvoh)已获FDA批准第2项适应症,用于治疗成人中度至重度活动性克罗恩病。Mirikizumab继2023年10月被批准为治疗中度至重度活动性成人溃疡性结肠炎(UC)的同类首创疗法之后,现在又被批准用于治疗两种类型的炎症性肠病(IBD)。

金融界
16 Jan
1月15日,礼来(LLY.US)宣布,其IL-23p19单抗mirikizumab(Omvoh)已获FDA批准第2项适应症,用于治疗成人中度至重度活动性克罗恩病。Mirikizumab继2023年10月被批准为治疗中度至重度活动性成人溃疡性结肠炎(UC)的同类首创疗法之后,现在又被批准用于治疗两种类型的炎症性肠病(IBD)。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10